Ergoteles’s KalVista Pharmaceuticals KALV Stock Holding History

Ergoteles’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,863	Closed	-$87K	–	1505
2022 Q4	$87K	Buy	+12,863	New	+$68.9K	﹤0.01%	1239

Other funds holding KALV

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Ergoteles's KALV Position: Q1 2023 in Review

Ergoteles sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 12,863 shares — an estimated $87K sold.

Ergoteles first reported a position in KALV in Q4 2022 and held it in 1 quarter. The position peaked at $87K in Q4 2022. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

Ergoteles reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 12,863 KalVista Pharmaceuticals shares in Q1 2023, an estimated $87K.
Ergoteles first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Ergoteles's KalVista Pharmaceuticals position peaked at $87K in Q4 2022.
88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.